A Phase 3 interventional study of Pregabalin and placebo in Post Herpetic Neuralgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 146 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing pregabalin in Neuralgia, Postherpetic — 3 open to participants now, 3 under way, 1 of them phase 3. Pregabalin · Neuralgia, Postherpetic.
Among the 15 studies testing pregabalin in Neuralgia, Postherpetic, this one has the largest enrollment, is one of 2 that started in 2011, is one of 5 in phase 3, and was the 9th registered.
197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.
Browse Neuralgia, Postherpetic studies →3 of the 15 studies testing pregabalin in Neuralgia, Postherpetic are open now, in 3 countries. Recruiting first, the newest first:
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–75
Zhejiang Chinese Medical University · Sites in China
Ages 50–80
Neurodawn Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 806 is above the median of 94 across 163 interventional studies indexed under Neuralgia, Postherpetic.
Median enrollment 126 across the 15 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 15 have an industry lead sponsor. The 9 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 8 studies filed under Neuralgia, Postherpetic — fewer than ten, so there is no comparison to draw.
1 of the studies testing pregabalin in Neuralgia, Postherpetic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing pregabalin in Neuralgia, Postherpetic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pregabalin
Drug: placebo
Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks
Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks
Number of Participants With Loss of Therapeutic Response.
Loss of Therapeutic Response (LTR) is defined as \<30% pain response relative to the single blind phase baseline or patient discontinuation due to lack of efficacy or adverse events in the double blind phase of the study. For the calculation of \<30% pain response relative to baseline, baseline will be defined as the mean of the last 7 observations prior to the start of SB treatment, which will be compared with the 7 days rolling average of pain response in DB phase. Participants may be discontinued due to lack of efficacy in this study at the discretion of the study physician.
Time frame: 13 Weeks
Participants With Secondary LTR Based on 5 Day Rolling Average Diary Results
A secondary LTR endpoint (S-LTR) was defined as the 5 day rolling average pain score during DB, compared to the 5 day randomization baseline pain score. As a secondary endpoint, S-LTR was defined as: 1. At least a 30% increase in the 5 days rolling average pain score during DB relative to the 5 Day randomization baseline pain score 2. A 5 days rolling average pain score ≥4. Participants who discontinue due to lack of efficacy or adverse events in the DB phase of the study will also be counted as an LTR.
Time frame: 13 Weeks
Percentage of Participants With 30% Reduction in the Mean Pain Score.
The 30% pain responders were defined as participants with at least a 30% reduction in the mean pain score from SB baseline to DB endpoint.
Time frame: 13 Weeks
Percentage of Participants With 50% Reduction in the Mean Pain Score.
The 50% pain responders were defined as participants with at least a 50% reduction in the mean pain score from SB baseline to DB endpoint.
Time frame: 13 Weeks
Change From Baseline to Endpoint in Weekly Mean Pain Score.
The pain numeric rating scale (NRS Pain) consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain
Time frame: SB Baseline (Enrollment) to Week 19 and DB Baseline (Week 6) to Week 19
Change in the Weekly NRS-Pain (1-Week Recall).
The pain numeric rating scale (NRS Pain) consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain. Participants were asked to rate their pain over the past week.
Time frame: SB Baseline (Enrollment) to Week 19 and DB Baseline (Week 6) to Week 19
Change in the Medical Outcomes Study-Sleep Scale (MOS-SS).
The MOS-SS is a validated self administered questionnaire consisting of 12 items that assess key constructs of sleep. The scale has been found reliable and valid with good overall measurement properties. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9 item overall sleep problems index assessing sleep over the past week. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute.
Time frame: SB Baseline (BL) (Enrollment) to Week 19 and DB Baseline (Week 6) to Week 19
Change in the MOS-SS-Quantity of Sleep.
The MOS-SS is a validated self administered questionnaire consisting of 12 items that assess key constructs of sleep. The scale has been found reliable and valid with good overall measurement properties. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9 item overall sleep problems index assessing sleep over the past week. The item "Quantity of sleep" of MOS-SS is presented here.
Time frame: SB Baseline (BL) (Enrollment) to Week 19 and DB Baseline (Week 6) to Week 19
The MOS-SS-Optimal Sleep.
The MOS-SS is a validated self administered questionnaire consisting of 12 items that assess key constructs of sleep. The scale has been found reliable and valid with good overall measurement properties. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9 item overall sleep problems index assessing sleep over the past week. The optimal sleep score is a dichotomous 'Yes' or 'No' rating, where 'Yes' indicates optimal sleep (average 7-8 hours per night) and 'No' indicates not optimal sleep. The "percentage of participants with optimal sleep" is presented here.
Time frame: Week 6 and Week 19
Percentage of Participants With Change in the Patient Global Impression of Change (PGIC) Score
The PGIC is a participant-rated instrument that has been used in chronic pain and fibromyalgia studies to rate change in a patient's overall status. This single item instrument uses a 7 point Likert scale, anchored by (1) very much improved, to (7) very much worse.
Time frame: Week 19
Change in the Short Form 36 Health Survey (SF-36)
The SF 36 is a self administered, validated questionnaire that measures each of the following 8 health aspects: Physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception over the past week. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) where, higher scores indicate a better health related quality of life.
Time frame: Week 19
Change in Mean Daily Sleep Interference Scores
The pain related sleep interference item rating scale is scored on an 11 point numeric rating scale (NRS Sleep). It is self administered by the subject in order to rate how pain has interfered with their sleep during the past 24 hours, ranging from 0 (pain does not interfere with sleep) to 10 (completely interferes (unable to sleep due to pain)). Participants are to describe how their pain has interfered with their sleep during the past 24 hours by choosing the appropriate number on the numeric rating scale.
Time frame: Week 19
Change in Hospital Anxiety and Depression Scales (HADS)
The HADS is a self administered questionnaire that was designed to screen for the presence of a mood disorder in medically ill patients. To distinguish psychiatric presentations from physical illness, the items focus on subjective disturbance of mood rather than physical signs. The HADS contains 14 items rated on 4 point Likert type scales. Two subscales assess depression and anxiety. Each subscale consists of 7 statements, rated on a scale of 0 to 3 (0 = No anxiety or depression, to 3 = Severe feelings of anxiety or depression). Separate scores are calculated for each subscale ranging from 0 to 21. Higher scores denote greater severity of depression or anxiety
Time frame: Week 19
Change in the Brief Pain Inventory (BPI-sf)
The BPI sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. The BPI sf consists of 5 questions. Questions 1, 2, 3, and 4 measure pain on an 11 point scale from 0 (no pain) to 10 (worst pain possible). Question 5 consists of 7 item subsets which measure the level of interference of pain on daily functions on an 11 point scale from 0 (Does not interfere) to 10 (Completely interferes).
Time frame: Week 19
Percentage of Participants With Benefit From Treatment, Satisfaction With Treatment and Willingness to Continue Treatement (BSW)
The BSW is administered by the study physician or designated site personnel and consists of three single item measures designed to capture the patient's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy.
Time frame: Week 19
Number of Participants With Adverse Events
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A serious adverse event is any untoward medical occurrence at any dose that: Results in death; Is life-threatening (immediate risk of death); Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); or Results in congenital anomaly/birth defect. The study physician used the adjective "severe" to those AEs that interfere significantly with participant's usual function.
Time frame: Baseline to Week 20
Percentage of Participants With Suicidal Behaviour/Ideation
Percentage of participants with suicidal behavior/ideation were noted as Baseline, Weeks 6, 11, 15, 19 and 20.
Time frame: Baseline, Weeks 6, 11, 15, 19 and 20
A total of 129 centers in 17 countries screened subjects for the study, including 68 in the US, 6 in Bulgaria, 6 in Poland, 6 in Russia, 6 in the Ukraine, 5 in India, 5 in South Africa, 5 in Sweden, 4 in Slovakia, 3 in Colombia, 3 in Croatia, 3 in Germany, 2 in Denmark, 2 in Hong Kong, 2 in Serbia, 2 in Taiwan, and 1 in the Czech Republic.
| Milestone | Pregabalin Controlled Release (CR) DB | Placebo DB | Pregabalin CR SB |
|---|---|---|---|
| Started | 0 | 0 | 806 |
| Completed | 0 | 0 | 660 |
| Not completed | 0 | 0 | 146 |
| Withdrew: Reason unspecified | 0 | 0 | 8 |
| Withdrew: Enrolled but not treated | 0 | 0 | 5 |
| Withdrew: Related adverse event | 0 | 0 | 46 |
| Withdrew: Lack of efficacy | 0 | 0 | 32 |
| Withdrew: Withdrawal by subject | 0 | 0 | 29 |
| Withdrew: Lost to follow-up | 0 | 0 | 10 |
| Withdrew: Unrelated ae | 0 | 0 | 8 |
| Withdrew: Protocol violation | 0 | 0 | 8 |
| Milestone | Pregabalin Controlled Release (CR) DB | Placebo DB | Pregabalin CR SB |
|---|---|---|---|
| Started | 208 | 205 | 0 |
| Completed | 182 | 160 | 0 |
| Not completed | 26 | 45 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Protocol and gcp non-compliance | 4 | 3 | 0 |
| Withdrew: Reason unspecified | 7 | 4 | 0 |
| Withdrew: Withdrawal by subject | 6 | 15 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 |
| Withdrew: Lack of efficacy | 2 | 11 | 0 |
| Withdrew: Adverse event not related to study drug | 1 | 1 | 0 |
| Withdrew: Adverse event related to study drug | 5 | 7 | 0 |
Loss of Therapeutic Response (LTR) is defined as \<30% pain response relative to the single blind phase baseline or patient discontinuation due to lack of efficacy or adverse events in the double blind phase of the study. For the calculation of \<30% pain response relative to baseline, baseline will be defined as the mean of the last 7 observations prior to the start of SB treatment, which will be compared with the 7 days rolling average of pain response in DB phase. Participants may be discontinued due to lack of efficacy in this study at the discretion of the study physician.
| Participants | Pregabalin CR DB | Placebo DB |
|---|---|---|
| Number of Participants With Loss of Therapeutic Response. | 29 | 63 |
A secondary LTR endpoint (S-LTR) was defined as the 5 day rolling average pain score during DB, compared to the 5 day randomization baseline pain score. As a secondary endpoint, S-LTR was defined as: 1. At least a 30% increase in the 5 days rolling average pain score during DB relative to the 5 Day randomization baseline pain score 2. A 5 days rolling average pain score ≥4. Participants who discontinue due to lack of efficacy or adverse events in the DB phase of the study will also be counted as an LTR.
| Participants | Pregabalin CR DB | Placebo DB |
|---|---|---|
| Participants With Secondary LTR Based on 5 Day Rolling Average Diary Results | 49 | 87 |
The 30% pain responders were defined as participants with at least a 30% reduction in the mean pain score from SB baseline to DB endpoint.
| Percentage of participants | Pregabalin CR DB | Placebo DB |
|---|---|---|
| Percentage of Participants With 30% Reduction in the Mean Pain Score. | 95.6 | 83.8 |
The 50% pain responders were defined as participants with at least a 50% reduction in the mean pain score from SB baseline to DB endpoint.
| Percentage of participants | Pregabalin CR DB | Placebo DB |
|---|---|---|
| Percentage of Participants With 50% Reduction in the Mean Pain Score. | 88.3 | 68.6 |
The pain numeric rating scale (NRS Pain) consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain
| Units on a scale | Pregabalin CR DB | Placebo DB |
|---|---|---|
| SB Baseline to Week 19 | -4.89 ± 0.12 | -3.95 ± 0.12 |
| DB Baseline to Week 19 | -0.04 ± 0.11 | 0.87 ± 0.11 |
The pain numeric rating scale (NRS Pain) consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain. Participants were asked to rate their pain over the past week.
| Units on a scale | Pregabalin CR DB | Placebo DB |
|---|---|---|
| SB Baseline to Week 19 | -5.0 ± 0.13 | -3.9 ± 0.14 |
| DB Baseline to Week 19 | -0.1 ± 0.13 | 0.9 ± 0.13 |
The MOS-SS is a validated self administered questionnaire consisting of 12 items that assess key constructs of sleep. The scale has been found reliable and valid with good overall measurement properties. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9 item overall sleep problems index assessing sleep over the past week. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute.
| Units on a scale | Pregabalin CR DB | Placebo DB |
|---|---|---|
| Sleep Problems Index I-SB BL to wk 19(N=202,195) | -19.9 ± 1.09 | -16.7 ± 1.13 |
| Sleep Problems Index I-DB BL to wk 19(N=202,195) | 1.2 ± 1.05 | 4.4 ± 1.09 |
| SleepProblems Index II-SB BL to wk 19(N=202,195) | -21.2 ± 1.07 | -17.4 ± 1.11 |
| SleepProblems Index II-DB BL to wk 19(N=202,194) | 0.2 ± 1.01 | 4.3 ± 1.05 |
| Sleep Disturbance-SB BL to wk 19 | -28.3 ± 1.42 | -21.1 ± 1.48 |
| Sleep Disturbance-DB BL to wk 19 | -1.1 ± 1.31 | 7.6 ± 1.36 |
| Snoring-SB BL to wk 19(N=202,194) | -3.3 ± 1.57 | -4.7 ± 1.64 |
| Snoring-DB BL to wk 19(N=201,194) | -0.6 ± 1.41 | 0.8 ± 1.46 |
| Awaken short of breath/headache-SB BL to wk 19 | -11.9 ± 1.21 | -10.4 ± 1.26 |
| Awaken short of breath/headache-DB BL to wk 19 | -1.2 ± 1.23 | -0.2 ± 1.27 |
| Sleep adequacy-SB BL to wk 19 | 19.9 ± 1.83 | 17.5 ± 1.90 |
| Sleep adequacy-DB BL to wk 19(N=202,195) | -3.3 ± 1.82 | -6.0 ± 1.89 |
| Somnolence-SB BL to wk 19(N=202,195) | -12.0 ± 1.19 | -12.0 ± 1.23 |
| Somnolence-DB BL to wk 19(N=203,194) | -0.7 ± 1.15 | -0.9 ± 1.19 |
The MOS-SS is a validated self administered questionnaire consisting of 12 items that assess key constructs of sleep. The scale has been found reliable and valid with good overall measurement properties. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9 item overall sleep problems index assessing sleep over the past week. The item "Quantity of sleep" of MOS-SS is presented here.
| Hours | Pregabalin CR DB | Placebo DB |
|---|---|---|
| Quantity of sleep-SB BL to wk 19(N=203,192) | 0.9 ± 0.09 | 0.7 ± 0.10 |
| Quantity of sleep-DB BL to wk 19(N=202,192) | -0.1 ± 0.08 | -0.4 ± 0.09 |
The MOS-SS is a validated self administered questionnaire consisting of 12 items that assess key constructs of sleep. The scale has been found reliable and valid with good overall measurement properties. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9 item overall sleep problems index assessing sleep over the past week. The optimal sleep score is a dichotomous 'Yes' or 'No' rating, where 'Yes' indicates optimal sleep (average 7-8 hours per night) and 'No' indicates not optimal sleep. The "percentage of participants with optimal sleep" is presented here.
| Percentage of participants | Pregabalin CR DB | Placebo DB |
|---|---|---|
| Week 6 (N=208,205) | 58.7 ± 0.09 | 62.4 ± 0.10 |
| Week 19 (N=204,197) | 54.9 ± 0.08 | 54.8 ± 0.09 |
The PGIC is a participant-rated instrument that has been used in chronic pain and fibromyalgia studies to rate change in a patient's overall status. This single item instrument uses a 7 point Likert scale, anchored by (1) very much improved, to (7) very much worse.
| Percentage of participants | Pregabalin CR DB | Placebo DB |
|---|---|---|
| Very much improved | 31.5 | 23.1 |
| Much improved | 36.9 | 30.3 |
| Minimally improved | 16.7 | 19.0 |
| No change | 10.3 | 12.8 |
| Minimally worse | 2.5 | 7.2 |
| Much worse | 1.5 | 7.2 |
| Very much worse | 0.5 | 0.5 |
The SF 36 is a self administered, validated questionnaire that measures each of the following 8 health aspects: Physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception over the past week. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) where, higher scores indicate a better health related quality of life.
| Units on a scale | Pregabalin CR DB | Placebo DB |
|---|---|---|
| Physical Component-SB BL to wk 19(N=202,195) | 7.5 ± 0.54 | 5.6 ± 0.56 |
| Physical Component-DB BL to wk 19(N=202,195) | 0.1 ± 0.51 | -2.3 ± 0.53 |
| Mental Component-SB BL to wk 19(N=202,195) | 6.4 ± 0.62 | 5.5 ± 0.64 |
| Mental Component-DB BL to wk 19(N=202,195) | -1.1 ± 0.62 | -2.2 ± 0.64 |
| Physical functioning-SB BL to wk 19 | 11.7 ± 1.44 | 8.9 ± 1.49 |
| Physical functioning-DB BL to wk 19 | -1.4 ± 1.25 | -4.9 ± 1.29 |
| Role-Physical-SB BL to wk 19 | 18.9 ± 1.62 | 13.9 ± 1.67 |
| Role-Physical-DB BL to wk 19 | -2.4 ± 1.54 | -7.7 ± 1.60 |
| Bodily pain-SB BL to wk 19 | 31.0 ± 1.51 | 23.6 ± 1.56 |
| Bodily pain-DB BL to wk 19 | 1.4 ± 1.38 | -6.2 ± 1.43 |
| General Health Perception-SB BL to wk19(N=202,195) | 11.3 ± 1.05 | 8.2 ± 1.08 |
| General Health Perception-DB BL to wk19(N=202,195) | 1.4 ± 0.96 | -4.0 ± 1.00 |
| Vitality-SB BL to wk 19(N=202,195) | 13.7 ± 1.25 | 10.7 ± 1.30 |
| Vitality-DB BL to wk 19(N=202,195) | -3.5 ± 1.21 | -6.5 ± 1.25 |
| Social Functioning-SB BL to wk 19 | 18.5 ± 1.35 | 15.7 ± 1.39 |
| Social Functioning-DB BL to wk 19 | -2.1 ± 1.28 | -4.3 ± 1.32 |
| Role-Emotional-SB BL to wk 19 | 15.0 ± 1.43 | 11.6 ± 1.47 |
| Role-Emotional-DB BL to wk 19 | -1.4 ± 1.42 | -5.4 ± 1.47 |
| Mental Health-SB BL to wk 19(N=202,195) | 11.1 ± 1.05 | 9.5 ± 1.08 |
| Mental Health-DB BL to wk 19(N=202,195) | -1.3 ± 1.04 | -3.7 ± 1.08 |
The pain related sleep interference item rating scale is scored on an 11 point numeric rating scale (NRS Sleep). It is self administered by the subject in order to rate how pain has interfered with their sleep during the past 24 hours, ranging from 0 (pain does not interfere with sleep) to 10 (completely interferes (unable to sleep due to pain)). Participants are to describe how their pain has interfered with their sleep during the past 24 hours by choosing the appropriate number on the numeric rating scale.
| Units on a scale | Pregabalin CR DB | Placebo DB |
|---|---|---|
| SB Baseline to Week 19 (N=205,203) | -4.5 ± 0.11 | -3.5 ± 0.11 |
| DB Baseline to Week 19 (N=206,204) | -0.2 ± 0.10 | 0.7 ± 0.10 |
The HADS is a self administered questionnaire that was designed to screen for the presence of a mood disorder in medically ill patients. To distinguish psychiatric presentations from physical illness, the items focus on subjective disturbance of mood rather than physical signs. The HADS contains 14 items rated on 4 point Likert type scales. Two subscales assess depression and anxiety. Each subscale consists of 7 statements, rated on a scale of 0 to 3 (0 = No anxiety or depression, to 3 = Severe feelings of anxiety or depression). Separate scores are calculated for each subscale ranging from 0 to 21. Higher scores denote greater severity of depression or anxiety
| Units on a scale | Pregabalin CR DB | Placebo DB |
|---|---|---|
| HADS-Anxiety-SB Baseline to Week 19 | -1.8 ± 0.21 | -1.1 ± 0.21 |
| HADS-Anxiety-DB Baseline to Week 19 | 0.1 ± 0.19 | 0.9 ± 0.20 |
| HADS-Depression-SB Baseline to Week 19 | -1.8 ± 0.20 | -1.2 ± 0.21 |
| HADS-Depression-DB Baseline to Week 19 | 0.2 ± 0.19 | 0.8 ± 0.19 |
The BPI sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. The BPI sf consists of 5 questions. Questions 1, 2, 3, and 4 measure pain on an 11 point scale from 0 (no pain) to 10 (worst pain possible). Question 5 consists of 7 item subsets which measure the level of interference of pain on daily functions on an 11 point scale from 0 (Does not interfere) to 10 (Completely interferes).
| Units on a scale | Pregabalin CR DB | Placebo DB |
|---|---|---|
| Pain Severity Index-SB Baseline to Week 19 | -18.0 ± 0.47 | -13.8 ± 0.49 |
| Pain Severity Index-DB Baseline to Week 19 | -0.7 ± 0.43 | 3.1 ± 0.44 |
| Pain Interference Index-SB Baseline to Week 19 | -21.9 ± 0.71 | -17.2 ± 0.74 |
| Pain Interference Index-DB Baseline to Week 19 | -0.2 ± 0.67 | 4.0 ± 0.70 |
The BSW is administered by the study physician or designated site personnel and consists of three single item measures designed to capture the patient's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy.
| Percentage of participants | Pregabalin CR DB | Placebo DB |
|---|---|---|
| Benefit from treatment | 98.5 | 93.3 |
| Satisfaction with treatment | 96.0 | 90.7 |
| Willingness to continue treatment | 87.6 | 81.3 |
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A serious adverse event is any untoward medical occurrence at any dose that: Results in death; Is life-threatening (immediate risk of death); Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); or Results in congenital anomaly/birth defect. The study physician used the adjective "severe" to those AEs that interfere significantly with participant's usual function.
| Participants | Pregabalin CR DB | Placebo DB | Pregabalin CR SB |
|---|---|---|---|
| Participants with AEs | 80 | 63 | 441 |
| Participants with Serious AEs | 7 | 3 | 17 |
| Participants with Severe AEs | 9 | 3 | 35 |
Percentage of participants with suicidal behavior/ideation were noted as Baseline, Weeks 6, 11, 15, 19 and 20.
| Percentage of participants | Pregabalin CR DB | Placebo DB |
|---|---|---|
| SB BL(N=208,205) | 0 | 0.5 |
| Week 6 (N=208,205) | 0 | 0 |
| Week 11 (N=194,178) | 0 | 0 |
| Week 15 (N=183,167) | 0 | 0 |
| Week 19 (N=204,197) | 0 | 0 |
| Week 20 (N=199,194) | 0 | 0 |
Collected over Baseline to Week 20. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin CR DB | — | 7/208 (3.4%) | 7/208 (3.4%) |
| Placebo DB | — | 3/205 (1.5%) | 1/205 (0.5%) |
| Pregabalin CR SB | — | 17/801 (2.1%) | 202/801 (25.2%) |
| Event | Pregabalin CR DB | Placebo DB | Pregabalin CR SB |
|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/208 | 1/205 | 0/801 |
| BronchopneumoniaInfections and infestations | 0/208 | 1/205 | 0/801 |
| Cerebrovascular disorderNervous system disorders | 0/208 | 1/205 | 0/801 |
| Anaemia of chronic diseaseBlood and lymphatic system disorders | 1/208 | 0/205 | 0/801 |
| Cardiac failureCardiac disorders | 1/208 | 0/205 | 0/801 |
| Acute sinusitisInfections and infestations | 1/208 | 0/205 | 0/801 |
| Perirectal abscessInfections and infestations | 1/208 | 0/205 | 0/801 |
| Back painMusculoskeletal and connective tissue disorders | 1/208 | 0/205 | 0/801 |
| SciaticaNervous system disorders | 1/208 | 0/205 | 0/801 |
| Renal massRenal and urinary disorders | 1/208 | 0/205 | 0/801 |
| Event | Pregabalin CR DB | Placebo DB | Pregabalin CR SB |
|---|---|---|---|
| DizzinessNervous system disorders | 7/208 | 1/205 | 137/801 |
| SomnolenceNervous system disorders | 1/208 | 0/205 | 91/801 |
Baseline analysis population description consisted of all participants randomized to the DB phase who received at least 1 dose of study medication in the DB phase (full analysis set).
| Age, Customized(Participants) | Pregabalin CR DB | Placebo DB | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| 18-44 years | 26 | 24 | 50 |
| 45-64 years | 86 | 78 | 164 |
| ≥65 years | 96 | 103 | 199 |
| Sex: Female, Male(Participants) | Pregabalin CR DB | Placebo DB | Total |
|---|---|---|---|
| Female | 134 | 122 | 256 |
| Male | 74 | 83 | 157 |
Showing the first 100 of 146 sites across 17 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2011, a primary completion of Sep 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →